Pfizer: presents results of pivotal ELEVATE study

(CercleFinance.com) - Pfizer has presented the results from the pivotal ELEVATE study demonstrating the potentially best-performing profile of Etrasimod in ulcerative colitis (UC).


The data was presented as a late-breaking presentation at Digestive Disease Week (DDW) 2022.

The two Phase 3, multi-centre, randomised, placebo-controlled trials met all key primary and secondary endpoints, with etrasimod demonstrating a safety profile consistent with previous studies.

UC is a chronic inflammatory bowel disease that affects approximately 3.8 million people in North America and Europe.



Copyright (c) 2022 CercleFinance.com. All rights reserved.